Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.

Literature DB >> 22290981

In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.

Kerin L Tyrrell¹, Diane M Citron, Yumi A Warren, Ellie J C Goldstein.

Abstract

TD-1792 is a multivalent glycopeptide-cephalosporin heterodimer antibiotic with potent activity against Gram-positive bacteria. We tested TD-1792 against 377 anaerobes and 34 strains of Corynebacterium species. Against nearly all Gram-positive strains, TD-1792 had an MIC₉₀ of 0.25 μg/ml and was typically 3 to 7 dilutions more active than vancomycin and daptomycin.

Entities: Chemical Species

Mesh：

Substances：

Year: 2012 PMID： 22290981 PMCID： PMC3318369 DOI： 10.1128/AAC.06274-11

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

12 in total

Review 1. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.

Authors: Jean-Winoc Decousser; Nadège Bourgeois-Nicolaos; Florence Doucet-Populaire
Journal: Expert Rev Anti Infect Ther Date: 2007-08 Impact factor: 5.091

2. Exploring the positional attachment of glycopeptide/beta-lactam heterodimers.

Authors: Daniel D Long; James B Aggen; Jason Chinn; Seok-Ki Choi; Burton G Christensen; Paul R Fatheree; David Green; Sharath S Hegde; J Kevin Judice; Koné Kaniga; Kevin M Krause; Michael Leadbetter; Martin S Linsell; Daniel G Marquess; Edmund J Moran; Matthew B Nodwell; John L Pace; Sean G Trapp; S Derek Turner
Journal: J Antibiot (Tokyo) Date: 2008-10 Impact factor: 2.649

3. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.

Authors: Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen T Fernandez
Journal: Antimicrob Agents Chemother Date: 2006-08 Impact factor: 5.191

4. Diabetic foot infections: a study of microorganisms associated with the different Wagner grades.

Authors: N A Pathare; A Bal; G V Talvalkar; D U Antani
Journal: Indian J Pathol Microbiol Date: 1998-10 Impact factor: 0.740

5. Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic.

Authors: Johanne Blais; Stacey R Lewis; Kevin M Krause; Bret M Benton
Journal: Antimicrob Agents Chemother Date: 2011-12-27 Impact factor: 5.191

6. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.

Authors: Kimberly D Leuthner; Celine Vidaillac; Chrissy M Cheung; Michael J Rybak
Journal: Antimicrob Agents Chemother Date: 2010-06-28 Impact factor: 5.191

7. Prevalence of Corynebacteria in diabetic foot infections.

Authors: A N Bessman; P J Geiger; H Canawati
Journal: Diabetes Care Date: 1992-11 Impact factor: 19.112

8. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.

Authors: Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal: Antimicrob Agents Chemother Date: 2004-06 Impact factor: 5.191

Review 5. The multifaceted nature of antimicrobial peptides: current synthetic chemistry approaches and future directions.

Authors: Bee Ha Gan; Josephine Gaynord; Sam M Rowe; Tomas Deingruber; David R Spring
Journal: Chem Soc Rev Date: 2021-07-05 Impact factor: 54.564

5 in total

In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.

Review 1. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.

2. Exploring the positional attachment of glycopeptide/beta-lactam heterodimers.

3. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.

4. Diabetic foot infections: a study of microorganisms associated with the different Wagner grades.

5. Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic.

6. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.

7. Prevalence of Corynebacteria in diabetic foot infections.

8. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.

9. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers.

10. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents.

Review 1. Antianaerobic antimicrobials: spectrum and susceptibility testing.

Review 2. Actinomyces and related organisms in human infections.

Review 3. Antibiotics and bacterial resistance in the 21st century.

4. Developments in Glycopeptide Antibiotics.

Review 5. The multifaceted nature of antimicrobial peptides: current synthetic chemistry approaches and future directions.